Drug intelligence / Profile preview

RLY-8161

Development stage: Phase 2
Lead developer: Relay Therapeutics
Modality: Small Molecules
Administration: Oral (inferred From Typical Small Molecule Oncology Drug Development; Not Explicitly Stated)

Overview

RLY-8161 is a small molecule inhibitor targeting NRAS, an oncogene in the RAS family of signaling proteins. It is being developed by Relay Therapeutics for the treatment of solid tumors harboring NRAS mutations. The drug is currently in preclinical development and represents a novel approach to inhibiting GTPase NRas, which has historically been considered a challenging target in oncology due to its role as an oncogenic driver in various cancers[1][2][4][7].

Other names: NRAS inhibitor (Relay)

Targets

NRAS (Neuroblastoma RAS viral oncogene homolog)

Beyond the preview

Go deeper on RLY-8161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLY-8161.